[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100336956":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":31,"responsibleParty":49,"collaborators":20,"id":51,"slug":20,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},{"fullName":5,"class":6},"3D Medicines","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects with MSI-H\u002FdMMR","EXPERIMENTAL","patients receive 600 mg of the KN035 Subcutaneously every 3 weeks",[13],"Biological: KN035",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","KN035","subcutaneous injection",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Lin Shen, MD","Peking Universtiy Cancer Hospital","PRINCIPAL_INVESTIGATOR",[27],{"name":23,"role":28,"phone":29,"phoneExt":20,"email":30},"CONTACT","86-10-88196340","doctorshenlin@sina.cn",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Peking University Cancer Hospital, Peking University","RECRUITING","Beijing","Beijing Municipality","100010","China","CN",{"type":41,"coordinates":42},"Point",[43,44],116.39723,39.9075,{"lat":44,"lon":43},[47],{"name":23,"role":28,"phone":48,"phoneExt":20,"email":30},"86-010-88196340",{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100336956",false,"NCT03667170","KN035 for dMMR\u002FMSI-H Advanced Solid Tumors","Study of KN035 as Monotherapy in Patients With Advanced Mismatched Repair Deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed locally advanced or metastatic colorectal carcinoma or other malignant solid tumors.\n* Confirmed MMR deficient or MSI-H status.\n* At least one measureable lesion.\n* Eastern Cooperative Oncology Group performance status of 0 or 1 .\n* Life expectancy of greater than 12 weeks.\n* Adequate hematologic and organ function.\n\nExclusion Criteria:\n\n* Currently participated in a study of an investigational agent and received trial treatment, or used an investigational device within 4 weeks of the first dose of medication in this study. Patients who have had specific anti-tumor treatment within 2 weeks prior to the first dose of study.\n* Patients who have not recovered to CTCAE Grade 1 or better from related side effects of any prior antineoplastic therapy.\n* Has received prior therapy with an immune check point agonist\u002Finhibitor.\n* Patients who have undergone major surgery within 4 weeks of dosing of investigational agent.\n* Has a known additional malignancy that is progressing or requires active treatment within the past 5 years.\n* Known active central nervous system metastases and\u002For carcinomatous meningitis.\n* Active autoimmune disease that has required systemic treatment.\n* Patients who have known history of infection with HIV.\n* Patients with evidence of interstitial lung disease.\n* Patients who have known history of any major cardiac abnormalities.\n* Patient who is not willing to apply highly effective contraception during the study.\n* Patients who have other concurrent severe and\u002For uncontrolled medical conditions that would, in the investigator's judgment, contraindicate patient participation in the clinical study.","ALL","18 Years",{"count":60,"type":61},200,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with KN035 monotherapy.\n\nFor colorectal cancer participants, who are required to have been previously treated with standard therapies , other solid tumor participants, who are required to have been previously treated with at least one line of systemic standard of care therapy.",[67],"Solid Tumor",[69,70,71,72],"MSI-H","dMMR","Colorectal cancer","Non-Colorectal Cancers","2026-03-23",{"date":75,"type":76},"2026-03-25","ACTUAL",{"date":78,"type":76},"2018-08-22",{"date":80,"type":61},"2026-12-30",{"name":82,"class":6},"3D Medicines (Sichuan) Co., Ltd.",1]